Author: Trial Expert

1

Marketing Authorization & Regulatory Requirements For Drug Registration In Thailand

Generic drug registration in Thailand can be a streamlined process, particularly if you understand the relevant regulations and requirements. Familiarity with the regulatory landscape and compliance criteria can significantly simplify the application and approval process for generic drug registration in Thailand, making it a more manageable and efficient undertaking. Thailand is the second-largest healthcare market […]

Read More →
1

Singapore Clinical Trial Regulatory Process

Singapore has a well-established regulatory framework for clinical trials, overseen by the Health Sciences Authority (HSA). The HSA ensures that clinical trials conducted in Singapore adhere to ethical principles and Good Clinical Practice (GCP) guidelines. This article was last updated on October 24. Singapore is considered as the R&D pioneer in Asia with highly qualified […]

Read More →
0

Clinical Trial Regulatory – Ukraine

Ukraine, the eighth largest European country by population, has often been overlooked as a clinical trial site, yet remains an attractive location for multinational companies for its clinical studies potential. Ukraine is one of the most attractive regions of the post-Soviet area in terms of clinical research because of its Vast population which is concentrated […]

Read More →
1

Japan (PMDA) – Clinical Trial Regulatory & Approval Process

Japan has clear and well-structured regulations for clinical trials. These rules help ensure the safety and effectiveness of new drugs. The government provides guidelines that drug developers must follow. The approval process is efficient, making Japan an attractive location for clinical trials. With a large market and strong regulatory support, Japan offers many benefits for […]

Read More →
0

Russia – Clinical Trial Regulatory Process

Russia has become an increasingly attractive venue for conducting clinical trials for international pharmaceutical companies. Russian clinics and principal investigators have proven to be highly capable of conducting clinical research at a level of quality not less than that of investigators in Western Europe and North America. Clinical trials in Russia Sponsors are considering Russia […]

Read More →
0

Rosacea – Clinical Trial Feasibility

Rosacea is a common chronic inflammatory skin condition that causes redness and visible blood vessels on the face. It may also produce small, red, pus-filled bumps. Rosacea can be mistaken for acne, eczema, or a skin allergy. In the US more than 14 million people are estimated living with Rosacea. What is Rosacea? Rosacea is […]

Read More →
1

China Medical Device Regulations Amendments

China has brought significant reforms in its regulatory system for pharmaceutical industry and clinical trials. In its continuous drive to improve the system, recently China’s Food and Drug Administration (CFDA) announced a major overhaul of its medical device regulations as well. To the current regulations, China has made significant changes. Summarily, 12 articles were newly […]

Read More →
0

Diabetic Foot Ulcer – Clinical Trial Feasibility

Foot ulcers refer to a patch of broken-down skin usually on the lower leg or feet. In diabetics, when blood sugar levels are high or fluctuate regularly, skin that would normally heal may not properly repair itself because of nerve damage. therefore start a foot ulcer. It occurs in 15% of people with diabetes and precedes […]

Read More →
0

Glomerulonephritis – Clinical Trial Feasibility

Glomerulonephritis (GN) is a serious kidney disorder that can lead to end-stage renal disease (ESRD), serious morbidity, or death. Worldwide, IgA Nephropathy (Berger disease) is the most common cause of GN. IgA nephropathy is an autoimmune disease and is one of the most common kidney diseases, other than those caused by diabetes or high blood pressure. […]

Read More →
3

Changing Clinical Trials Scenario In China

China is the largest clinical trial market in Asia and the 5th largest in the world. In recent years there was a remarkable increase in Phase I-III clinical trials. Understandably, there must be something significant happening, which brought this change. The recent changes in policies and regulations in China have brought a lot of cheer from […]

Read More →